ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
To evaluate the efficacy and safety of ASKC202 combined with limertinib as the first-line treatment for locally advanced or metastatic NSCLC
Epistemonikos ID: d93499d4c45dbd6ee5d76568e17255f0ae350b15
First added on: Oct 28, 2026